The Committee for Advanced Therapies (CAT) is the committee at the European Medicines Agency that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (ATMPs) and following scientific developments in the field. It is a multidisciplinary committee, gathering together some of the best available experts in Europe.
It was established in accordance with Regulation (EC) No 1394/2007 on ATMPs.
- See the full overview of the CAT's role.
The members of the CAT are appointed for a renewable period of three years. The chair and vice-chair are elected from its members for a term of three years, which may be renewed once.
The CAT is composed of:
- five members or co-opted members of the Committee for Medicinal Products for Human Use (CHMP), with their alternates. These members are appointed by the CHMP itself;
- one member and one alternate appointed by each European Union (EU) Member State that is not represented by the members and alternates appointed by the CHMP;
- two members and two alternates appointed by the European Commission to represent clinicians;
- two members and two alternates appointed by the European Commission to represent patient associations.
- See full meeting plan for this year.